Abstracts tagged "imatinib and systemic sclerosis"

Abstract Number: 878 • 2014 ACR/ARHP Annual Meeting
Luminex and Autoantigen Microarray Analysis of Sera from Patients with Diffuse Cutaneous Systemic Sclerosis Reveals Changes Associated with Imatinib Mesylate Treatment
D. James Haddon¹, Hannah Wand², Paul J. Utz¹, Robert F. Spiera³, Jessica K. Gordon³ and Lorinda Chung⁴, ¹Medicine, Stanford University School of Medicine, Stanford, CA, ²Stanford University School of Medicine, Stanford, CA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose Tyrosine kinase inhibitors (TKIs), including imatinib mesylate, have been studied for the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc). In a previously reported single…
Abstract Number: 1715 • 2012 ACR/ARHP Annual Meeting
Imatinib Mesylate (Gleevec™) in the Treatment of Diffuse Cutaneous Systemic Sclerosis: Results of a 24 Month Open Label, Extension Phase
Jessica K. Gordon¹, Morgana L. Davids², Kamini Doobay², Jamie N. Mersten¹, Cynthia Magro³, Horatio F. Wildman⁴, Stephen L. Lyman⁵, Mary K. Crow⁶ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medicine/Rheumatology, Hospital for Special Surgery, New York, NY, ³Dermatopathology, Weill-Cornell Medical Center, New York, NY, ⁴Dermatology, Weill-Cornell Medical Center, New York, NY, ⁵Research, Hospital for Special Surgery, New York, NY, ⁶Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Imatinib mesylate (IM) has been shown to decrease fibrosis in preclinical models and is a treatment of interest for Systemic Sclerosis (SSc). We have…
Abstract Number: 1475 • 2012 ACR/ARHP Annual Meeting
Does Skin Gene Expression Profile Predict Response to Imatinib?
Shervin Assassi¹, Jeffrey T. Chang², Dinesh Khanna³, Xiaochun Liu¹, Daniel Furst⁴ and Maureen D. Mayes⁵, ¹Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ²University of Texas Health Science Center at Houston, Houston, TX, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ⁵Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Imatinib is a potent inhibitor of TGF-β signaling. Furthermore, a subgroup of SSc patients shows a prominent TGF-β gene expression signature in skin biopsy…
Abstract Number: 787 • 2012 ACR/ARHP Annual Meeting
Aberrant Adipogenesis in the Pathogenesis of Scleroderma
Roberta Goncalves Marangoni¹, Jun Wei², Monique E. Hinchcliff¹, Feng Fang³, Warren Tourtellotte⁴ and John Varga⁵, ¹Division of Rheumatology, Northwestern University Medical School, Chicago, IL, ²Rheumatology Division, Northwestern University, Chicago, IL, ³Rheumatology Division, Northwestern University Medical School, Chicago, IL, ⁴Pathology, Northwestern University Medical School, Chicago, IL, ⁵Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Skin fibrosis in systemic sclerosis (SSc) is associated with loss of subcutaneous adipose tissue (SCAT) and reduction in adiponectin. The mechanism underlying SCAT atrophy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].